Embargo: 0001H Sao Paulo local time, Wednesday 1 November
[Sao Paulo, 1 November 2017] New data on hepatitis C released by the Polaris Observatory*
and presented today at the World Hepatitis Summit (WHS) in Sao Paulo, Brazil show that
nine countries — Australia, Brazil, Egypt, Georgia, Germany, Iceland, Japan, the
Netherlands and Qatar — are on course to eliminate hepatitis C by 2030.
Worldwide, viral hepatitis kills more than one million people each year, and more than 300
million people are chronically infected with hepatitis B or C. Yet, with the development of
highly-effective direct acting antivirals (DAAs) for hepatitis C and the increasing rates of
hepatitis B treatment and vaccination coverage globally, elimination of viral hepatitis has
become a real possibility.
“This new data shows that elimination of hepatitis C is possible but it also shows more must
be done to support governments in tackling viral hepatitis,” said Charles Gore, President of
the World Hepatitis Alliance. “The World Hepatitis Summit offers governments the
opportunity to learn from other countries and public health experts, in an effort to speed up
progress to elimination.”
Since the adoption of World Health Organization’s (WHO) elimination targets in 2016, which
include a 90% reduction of new hepatitis B and C infections and a 65% reduction in hepatitis
B and C related mortality by 2030, some countries are making great strides yet multiple
factors preventing progress remain for the majority. These include a lack of political will and
global funding mechanisms, poor data and surveillance, access to diagnostics and
medicines and poor diagnosis rates (approx. 10% worldwide for hepatitis B and 20% for
hepatitis C), that together mean that many countries are struggling to reach the targets.
Some key countries which are being highlighted at the Summit for their innovative work to
eliminate viral hepatitis are Brazil, Egypt, Australia and Georgia. In 2017, Egypt pledged to
test 30 million for hepatitis C by the end of 2018 by implementing mass screening initiatives
(including assistance from the military), as well as mass producing generic copies of DAA
drugs for under US $200 per 12-week course.
Meanwhile, WHS host nation Brazil has committed to gradually lift treatment restrictions in
2018, meaning that the country will be able to treat all people infected with hepatitis C,
ensuring it is on target to eliminate hepatitis C. Previously, treatment was restricted to only
the sickest patients with advanced liver disease.
“Brazil has championed the cause of hepatitis on the world stage for many years and has
pushed for an intensified global hepatitis response,” says Adele Schwartz Benzaken, director
of the Brazilian Ministry of Health’s Department of Surveillance, Prevention and Control of
STIs, HIV/AIDS and Viral Hepatitis. “In addition to the work we have already done on
hepatitis B, opening up vaccination to the whole population, we are now gradually removing
the restrictions on access to hepatitis C treatment – so that, from 2018 on, the entire infected
population can be treated, not just the sickest.”
The Australian government responded to the call for universal access to the hepatitis C
DAAs with an AUS $1billion dollar investment over 5 years. This risk-sharing agreement with
pharmaceutical companies provides government-funded treatment to all adults without
restriction and has paved the way for the elimination of hepatitis C by 2030. More than
30,000 patients with hepatitis C were treated and cured in 2016.
“What we are seeing is that some countries, especially those with a high burden, are making
the elimination of viral hepatitis a priority and are looking at innovative ways to do it,” said
Home Razavi, Director of CDA. “However, it will be near-impossible for most other countries
to meet the WHO targets without a huge scale-up in political will and access to diagnostics
Although only a handful of countries are currently on track to reach the WHO’s elimination
targets, there are a number of other countries which are making progress. Mongolia,
Gambia, and Bangladesh have shown real political will and, along with Brazil, Georgia and
Egypt, are spearheading the NOhep Visionary Programme** in their region, due to their
commitment to ending their epidemics.
“Because viral hepatitis has been neglected for so long, much needs to be done rapidly to
make up for lost time,” concluded Gore. “In that context, the Summit, a biennial event,
focuses on the public health approach to viral hepatitis and acts as the central forum for
countries to share their experience and best practice in order to drive rapid advances in
Tony Kirby, Media Consultant for World Hepatitis Summit. T) +44 7834 385827 E)
Tara Farrell, Head of Communications, World Hepatitis Alliance. T) +44(0)7761625256
Media contacts in Brazilian Ministry of Health’s Department of Surveillance,
Prevention and Control of STIs, HIV/AIDS and Viral Hepatitis: Grace Perpetuo T) +55
61 99968 6541 E) firstname.lastname@example.org / Alexandre Magno T) +55 61 98163
9867 E) email@example.com
For country level data from Polaris, see:
About Viral Hepatitis
Viral hepatitis is inflammation of the liver caused by a virus. WHO say that the total deaths
cause by viral hepatitis, including acute cases, cirrhosis and liver cancer account for 1.34
million deaths globally. There are five different hepatitis viruses – hepatitis A, B, C, D and E.
Hepatitis A is spread mainly through ingestion of contaminated food and water and the
disease is often endemic in countries with a lack of safe water and poor sanitation. Hepatitis
B is transmitted through contact with the blood or other bodily fluids of an infected person
and approximately 257 million people are living with chronic infections. Hepatitis C is mainly
spread through blood-to-blood contact such as unsafe injection practices and inadequate
sterilisation of medical equipment. Today, 69 million people are living with the disease.
Hepatitis D is passed on through contact with infected blood and only occurs in people who
are already infected with hepatitis B. Hepatitis E, like hepatitis A, is transmitted through
ingesting contaminated food or water.
The World Hepatitis Summit 2017
Between 1 – 3 November 2017 a global audience of civil society groups, World Health
Organization and its Member States, patient organisations from the World Hepatitis
Alliance’s 252 members, people living with viral hepatitis, policy-makers, public health
scientists and funders have come together in Brazil, at the World Hepatitis Summit, to
galvanise the global response to viral hepatitis. The World Hepatitis Summit is a joint
initiative between the World Health Organization (WHO) and the World Hepatitis Alliance – in
collaboration with a different host country for each Summit. Its mission is to support
countries in meeting the targets needed to eliminate viral hepatitis.
The World Hepatitis Alliance
The World Hepatitis Alliance (WHA) is a patient-led and patient driven non-governmental
organisation. With 252 member patient groups from 84 countries, WHA works with
governments, national members and other key partners to raise awareness of viral hepatitis
and influence global change. To achieve a world free from viral hepatitis, WHA provides
global leadership in advocacy, awareness-raising and the fight to end its social injustice.
* About the Center for Disease Analysis
The CDA is a public health research firm based Lafayette, Colorado, USA, with expertise in
epidemiology and disease modelling. One of its main areas of focus is the epidemiology of
the hepatitis B, C, and D viruses, which is done through its Polaris Observatory data centre.
** NOhep Visionaries Programme
The NOhep Visionaries Programme brings together key decision makers in governments,
medical professionals and activists to accelerate action to eliminate viral hepatitis by 2030.
The NOhep Visionaries Programme is part of NOhep, the global movement to eliminate viral
© The Hepatitis Foundation of New Zealand 2016